Brigatinib/Brigatinib: second-generation ALK inhibitor targeted drugs

Brigatinib/Brigatinib (Brigatinib) is a highly effective second-generation ALK inhibitor and belongs to the category of targeted drugs. Targeted drugs are specifically designed to target specific molecules or signaling pathways in tumor cells, aiming to achieve precise strikes and reduce toxic side effects on healthy cells. Brigatinib inhibits the proliferation and migration of tumor cells by precisely inhibiting the function of the ALK protein.

Compared with traditional chemotherapy methods, brigatinib stands out for its high selectivity and specificity, bringing a new treatment strategy to patients with non-small cell lung cancer, especially ALK-positive patients. Not only can this drug be taken orally, but its ability to inhibit kinases is 12 times that of the first-generation drug crizotinib, showing significant clinical effects.

In addition, brigatinib also exhibits inhibition of ROS1 kinase and has been shown to be active against multiple ALK mutations that lead to resistance to crizotinib in preclinical studies. In clinical trials, brigatinib showed impressive efficacy in patients with ALK-positive non-small cell lung cancer who had progressed after treatment with crizotinib, with an objective response rate as high as 72%, and the performance of the 180 mg dose group was particularly outstanding.

It is worth mentioning that brigatinib also shows strong activity in cases where otherALK inhibitors such as osimertinib and lorlatinib are ineffective. Studies have shown that compared with other established inhibitors, brigatinib has a stronger inhibitory effect and the ability to improve survival rates against specific drug-resistant mutations caused by ALK (such as G1202R and L1196M). These properties make brigatinib occupy an important position in the treatment of non-small cell lung cancer and provide patients with new hope.